Search

Aug 31, 2024
Alnylam's CEO Dr. Yvonne Greenstreet discusses HELIOS-B at the European Society of Cardiology Congress in London
Dr. Greenstreet shares her opinion of why she believes the data places vutrisiran in a competitive position to be a first line choice for...

Jun 24, 2024
Alnylam CEO Yvonne Greenstreet on today's HELIOS-B data
Yvonne Greenstreet shares her thoughts on key points of today's top-line, but as monotherapy and in combination, the potential market, and w

Jan 9, 2024
Alnylam CEO Yvonne Greenstreet previews 2024
Yvonne Greenstreet talks about how Alnylam has been moving RNAi beyond the liver and previews the year ahead, including HELIOS-B.